Accession Number:



Ebola Virus Disease Candidate Vaccines Under Evaluation in Clinical Trials

Descriptive Note:

Journal Article

Corporate Author:

USAMRIID Frederick United States

Personal Author(s):

Report Date:


Pagination or Media Count:



Filoviruses are the etiological agents of two human illnesses Ebola virus disease and Marburg virus disease. Until 2013, medical countermeasure development against these afflictions was limited to only a few research institutes worldwide as both infections were considered exotic due to very low case numbers. Together with the high case-fatality rate of both diseases, evaluation of any candidate countermeasure in properly controlled clinical trials seemed impossible. However, in 2013, Ebola virus was identified as the etiological agent of a large disease outbreak in Western Africa including almost 30,000 infections and more than 11,000 deaths, including case exportations to Europe and North America. These large case numbers resulted in medical countermeasure development against Ebola virus disease becoming a global public-health priority. This review summarizes the status quo of candidate vaccines against Ebola virus disease, with a focus on those that are currently under evaluation in clinical trials.

Subject Categories:

Distribution Statement: